You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTaurocholic Acid
Accession NumberDB04348  (EXPT03023)
TypeSmall Molecule
GroupsExperimental
DescriptionThe product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic. [PubChem]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5E090O0G3Z
CAS number81-24-3
WeightAverage: 515.703
Monoisotopic: 515.291673489
Chemical FormulaC26H45NO7S
InChI KeyWBWWGRHZICKQGZ-GIHLXUJPSA-N
InChI
InChI=1S/C26H45NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)/t15-,16-,17+,18+,19+,20+,21-,22-,24+,25+,26-/m1/s1
IUPAC Name
2-[(4R)-4-[(1S,2S,5S,7R,9R,10R,11S,14S,15R,16R)-5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]pentanamido]ethane-1-sulfonic acid
SMILES
C[[email protected]](CCC(=O)NCCS(O)(=O)=O)[C@@H]1CC[[email protected]]2[C@@H]3[[email protected]](O)C[[email protected]]4C[C@@H](O)CC[C@]4(C)[[email protected]]3C[C@@H](O)[C@]12C
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Bile salt-activated lipaseProteinunknownNot AvailableHumanP19835 details
GastrotropinProteinunknownNot AvailableHumanP51161 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Cerebrotendinous Xanthomatosis (CTX)DiseaseSMP00315
27-Hydroxylase DeficiencyDiseaseSMP00720
Bile Acid BiosynthesisMetabolicSMP00035
Familial Hypercholanemia (FHCA)DiseaseSMP00317
Congenital Bile Acid Synthesis Defect Type IIDiseaseSMP00314
Zellweger SyndromeDiseaseSMP00316
Congenital Bile Acid Synthesis Defect Type IIIDiseaseSMP00318
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Taurocholic Acid.Approved
AcetaminophenThe serum concentration of Taurocholic Acid can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Taurocholic Acid.Approved
AlbendazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Taurocholic Acid can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Taurocholic Acid can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Taurocholic Acid.Approved, Investigational
AmantadineThe serum concentration of Taurocholic Acid can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Taurocholic Acid.Approved, Investigational
Aminohippuric acidThe serum concentration of Taurocholic Acid can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Taurocholic Acid can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Taurocholic Acid can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Taurocholic Acid can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Taurocholic Acid can be increased when it is combined with Amsacrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Taurocholic Acid.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Taurocholic Acid.Approved, Investigational
AstemizoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Taurocholic Acid.Approved, Investigational
AtenololThe serum concentration of Taurocholic Acid can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Taurocholic Acid can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Taurocholic Acid.Approved, Investigational
AzelastineThe serum concentration of Taurocholic Acid can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Taurocholic Acid can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Taurocholic Acid can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Taurocholic Acid can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
BiperidenThe serum concentration of Taurocholic Acid can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Taurocholic Acid.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Taurocholic Acid.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Taurocholic Acid.Approved
BromocriptineThe serum concentration of Taurocholic Acid can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Taurocholic Acid can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Taurocholic Acid can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Taurocholic Acid.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Taurocholic Acid.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Taurocholic Acid.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Taurocholic Acid.Approved
CandesartanThe serum concentration of Taurocholic Acid can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Taurocholic Acid can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Taurocholic Acid.Approved
CarvedilolThe serum concentration of Taurocholic Acid can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Taurocholic Acid can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Taurocholic Acid.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Taurocholic Acid.Withdrawn
ChloroquineThe serum concentration of Taurocholic Acid can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Taurocholic Acid can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Taurocholic Acid can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Taurocholic Acid can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Taurocholic Acid.Approved
CitalopramThe serum concentration of Taurocholic Acid can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Taurocholic Acid can be increased when it is combined with Clarithromycin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Taurocholic Acid.Approved, Illicit
ClofazimineThe serum concentration of Taurocholic Acid can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Taurocholic Acid.Approved, Investigational
ClomipramineThe serum concentration of Taurocholic Acid can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Taurocholic Acid.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Taurocholic Acid.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Taurocholic Acid can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Taurocholic Acid.Approved
CobicistatThe serum concentration of Taurocholic Acid can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Taurocholic Acid.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Taurocholic Acid.Approved
ColforsinThe serum concentration of Taurocholic Acid can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Taurocholic Acid.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Taurocholic Acid.Approved
CyclophosphamideThe serum concentration of Taurocholic Acid can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Taurocholic Acid.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Taurocholic Acid.Approved
DaclatasvirThe serum concentration of Taurocholic Acid can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Taurocholic Acid can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Taurocholic Acid.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Taurocholic Acid.Approved, Investigational
DaunorubicinThe serum concentration of Taurocholic Acid can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Taurocholic Acid.Approved
DesipramineThe serum concentration of Taurocholic Acid can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Taurocholic Acid can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Taurocholic Acid can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Taurocholic Acid.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Taurocholic Acid can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Taurocholic Acid.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Taurocholic Acid.Approved
DigoxinThe serum concentration of Taurocholic Acid can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Taurocholic Acid can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Taurocholic Acid.Illicit
DiltiazemThe serum concentration of Taurocholic Acid can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Taurocholic Acid.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Taurocholic Acid.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Taurocholic Acid can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Taurocholic Acid can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Taurocholic Acid.Approved, Investigational
DoxorubicinThe serum concentration of Taurocholic Acid can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Taurocholic Acid can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Taurocholic Acid can be increased when it is combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Taurocholic Acid.Approved
ElbasvirThe serum concentration of Taurocholic Acid can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Taurocholic Acid.Approved, Investigational
EltrombopagThe serum concentration of Taurocholic Acid can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Taurocholic Acid can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Taurocholic Acid can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Taurocholic Acid.Approved, Investigational
ErgonovineThe serum concentration of Taurocholic Acid can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Taurocholic Acid can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Taurocholic Acid.Approved, Investigational
ErythromycinThe serum concentration of Taurocholic Acid can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Taurocholic Acid.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Taurocholic Acid can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Taurocholic Acid can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Taurocholic Acid.Approved
EtoposideThe serum concentration of Taurocholic Acid can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Taurocholic Acid can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Taurocholic Acid.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Taurocholic Acid.Approved
FelodipineThe serum concentration of Taurocholic Acid can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Taurocholic Acid can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Taurocholic Acid.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Taurocholic Acid.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Taurocholic Acid.Approved
FluconazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Taurocholic Acid can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Taurocholic Acid can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Taurocholic Acid.Approved
FluvoxamineThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluvoxamine.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Taurocholic Acid.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Taurocholic Acid.Approved
GenisteinThe serum concentration of Taurocholic Acid can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Taurocholic Acid can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Taurocholic Acid can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Taurocholic Acid can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Taurocholic Acid.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Taurocholic Acid.Withdrawn
HaloperidolThe serum concentration of Taurocholic Acid can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Taurocholic Acid can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Taurocholic Acid.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Taurocholic Acid.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Taurocholic Acid.Approved
ImipramineThe serum concentration of Taurocholic Acid can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Taurocholic Acid.Approved
IndinavirThe serum concentration of Taurocholic Acid can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Taurocholic Acid can be increased when it is combined with Indomethacin.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Taurocholic Acid.Approved, Investigational
IsavuconazoniumThe serum concentration of Taurocholic Acid can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Taurocholic Acid can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Taurocholic Acid can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Taurocholic Acid can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Taurocholic Acid.Approved
KetoconazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Taurocholic Acid.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Taurocholic Acid.Approved, Investigational
LansoprazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Taurocholic Acid can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Taurocholic Acid.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Taurocholic Acid.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Taurocholic Acid.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Taurocholic Acid.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Taurocholic Acid.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Taurocholic Acid.Approved
LevothyroxineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Taurocholic Acid can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Taurocholic Acid.Approved
LiothyronineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Taurocholic Acid can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Taurocholic Acid can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Taurocholic Acid can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Taurocholic Acid can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Taurocholic Acid can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Taurocholic Acid can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Taurocholic Acid can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Taurocholic Acid can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Taurocholic Acid can be decreased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Taurocholic Acid.Approved, Investigational
MaprotilineThe serum concentration of Taurocholic Acid can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Taurocholic Acid can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Taurocholic Acid can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Taurocholic Acid can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Taurocholic Acid can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Taurocholic Acid.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
MetoprololThe serum concentration of Taurocholic Acid can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Taurocholic Acid can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Taurocholic Acid can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Taurocholic Acid.Approved
MitomycinThe serum concentration of Taurocholic Acid can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Taurocholic Acid can be increased when it is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Taurocholic Acid.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Taurocholic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Taurocholic Acid.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
NaltrexoneThe serum concentration of Taurocholic Acid can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Taurocholic Acid can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Taurocholic Acid can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Taurocholic Acid can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Taurocholic Acid can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Taurocholic Acid.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Taurocholic Acid.Approved
NisoldipineThe serum concentration of Taurocholic Acid can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Taurocholic Acid can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Taurocholic Acid can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Taurocholic Acid.Approved
NorethisteroneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Taurocholic Acid.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Taurocholic Acid.Approved
OmeprazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Taurocholic Acid.Approved
P-NitrophenolThe serum concentration of Taurocholic Acid can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Taurocholic Acid can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Taurocholic Acid.Approved, Investigational
PantoprazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Taurocholic Acid can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Taurocholic Acid.Approved
PerindoprilThe serum concentration of Taurocholic Acid can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Taurocholic Acid can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
PimozideThe serum concentration of Taurocholic Acid can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Taurocholic Acid.Approved
Platelet Activating FactorThe serum concentration of Taurocholic Acid can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Taurocholic Acid.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Taurocholic Acid.Approved
PosaconazoleThe serum concentration of Taurocholic Acid can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Taurocholic Acid.Approved
PrazosinThe serum concentration of Taurocholic Acid can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
ProbenecidThe serum concentration of Taurocholic Acid can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Taurocholic Acid can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Taurocholic Acid can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Taurocholic Acid.Approved, Investigational
ProtriptylineThe serum concentration of Taurocholic Acid can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Taurocholic Acid.Approved
QuercetinThe serum concentration of Taurocholic Acid can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Taurocholic Acid.Approved
QuinacrineThe serum concentration of Taurocholic Acid can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Taurocholic Acid can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Taurocholic Acid can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Taurocholic Acid can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Taurocholic Acid.Approved, Investigational
ReboxetineThe serum concentration of Taurocholic Acid can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Taurocholic Acid can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Taurocholic Acid can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Taurocholic Acid.Approved, Investigational
RilpivirineThe serum concentration of Taurocholic Acid can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Taurocholic Acid.Approved, Investigational
RitonavirThe serum concentration of Taurocholic Acid can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Taurocholic Acid.Approved
RolapitantThe serum concentration of Taurocholic Acid can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Taurocholic Acid.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Taurocholic Acid.Approved, Vet Approved
SaquinavirThe serum concentration of Taurocholic Acid can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Taurocholic Acid can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Taurocholic Acid can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Taurocholic Acid.Approved
SertralineThe serum concentration of Taurocholic Acid can be increased when it is combined with Sertraline.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Taurocholic Acid.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Taurocholic Acid.Approved
SimvastatinThe serum concentration of Taurocholic Acid can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Taurocholic Acid can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Taurocholic Acid.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Taurocholic Acid.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Taurocholic Acid.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Taurocholic Acid.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Taurocholic Acid.Experimental
SpironolactoneThe serum concentration of Taurocholic Acid can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Taurocholic Acid can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Taurocholic Acid can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Taurocholic Acid can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Taurocholic Acid can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Taurocholic Acid can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Taurocholic Acid can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Taurocholic Acid can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Taurocholic Acid can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Taurocholic Acid can be decreased when it is combined with Tamoxifen.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Taurocholic Acid.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Taurocholic Acid.Approved
TelmisartanThe serum concentration of Taurocholic Acid can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Taurocholic Acid.Approved
TerazosinThe serum concentration of Taurocholic Acid can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Taurocholic Acid can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Taurocholic Acid can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Taurocholic Acid can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Taurocholic Acid.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Taurocholic Acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Taurocholic Acid.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Taurocholic Acid.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Taurocholic Acid.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Taurocholic Acid.Approved
TrazodoneThe serum concentration of Taurocholic Acid can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Taurocholic Acid can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Taurocholic Acid can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Taurocholic Acid can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Taurocholic Acid can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Taurocholic Acid can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Taurocholic Acid.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Taurocholic Acid.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Taurocholic Acid.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Taurocholic Acid.Approved
VenlafaxineThe serum concentration of Taurocholic Acid can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Taurocholic Acid can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Taurocholic Acid.Approved, Investigational
VincristineThe serum concentration of Taurocholic Acid can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Taurocholic Acid can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Taurocholic Acid.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Taurocholic Acid.Approved
ZimelidineThe serum concentration of Taurocholic Acid can be increased when it is combined with Zimelidine.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9774
Blood Brain Barrier+0.8416
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5136
P-glycoprotein inhibitor INon-inhibitor0.6229
P-glycoprotein inhibitor IINon-inhibitor0.7598
Renal organic cation transporterNon-inhibitor0.8476
CYP450 2C9 substrateNon-substrate0.7519
CYP450 2D6 substrateNon-substrate0.7972
CYP450 3A4 substrateSubstrate0.654
CYP450 1A2 substrateNon-inhibitor0.7814
CYP450 2C9 inhibitorNon-inhibitor0.8625
CYP450 2D6 inhibitorNon-inhibitor0.8685
CYP450 2C19 inhibitorNon-inhibitor0.8426
CYP450 3A4 inhibitorNon-inhibitor0.8612
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7175
Ames testNon AMES toxic0.6103
CarcinogenicityNon-carcinogens0.5359
BiodegradationNot ready biodegradable0.972
Rat acute toxicity2.0310 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.706
hERG inhibition (predictor II)Inhibitor0.5549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point125 dec °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0771 mg/mLALOGPS
logP0.79ALOGPS
logP-0.53ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)-1.1ChemAxon
pKa (Strongest Basic)0.28ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area144.16 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity132.19 m3·mol-1ChemAxon
Polarizability57.39 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taurinated bile acids and derivatives. These are bile acid derivatives containing a taurine conjugated to the bile acid moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassBile acids, alcohols and derivatives
Direct ParentTaurinated bile acids and derivatives
Alternative Parents
Substituents
  • Taurinated bile acid
  • Trihydroxy bile acid, alcohol, or derivatives
  • Hydroxy bile acid, alcohol, or derivatives
  • 7-hydroxysteroid
  • 3-beta-hydroxysteroid
  • Hydroxysteroid
  • 12-hydroxysteroid
  • 3-hydroxysteroid
  • Fatty acyl
  • N-acyl-amine
  • Fatty amide
  • Alkanesulfonic acid
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonic acid
  • Cyclic alcohol
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Polyol
  • Carboxamide group
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Triglyceride lipase activity
Specific Function:
Catalyzes fat and vitamin absorption. Acts in concert with pancreatic lipase and colipase for the complete digestion of dietary triglycerides.
Gene Name:
CEL
Uniprot ID:
P19835
Molecular Weight:
79320.93 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Transporter activity
Specific Function:
Ileal protein which stimulates gastric acid and pepsinogen secretion. Seems to be able to bind to bile salts and bilirubins. Isoform 2 is essential for the survival of colon cancer cells to bile acid-induced apoptosis.
Gene Name:
FABP6
Uniprot ID:
P51161
Molecular Weight:
14371.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
  2. Wolters H, Elzinga BM, Baller JF, Boverhof R, Schwarz M, Stieger B, Verkade HJ, Kuipers F: Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J Hepatol. 2002 Nov;37(5):556-63. [PubMed:12399219 ]
  3. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239 ]
  4. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. [PubMed:11343252 ]
  5. Mendoza ME, Monte MJ, Serrano MA, Pastor-Anglada M, Stieger B, Meier PJ, Medarde M, Marin JJ: Physiological characteristics of allo-cholic acid. J Lipid Res. 2003 Jan;44(1):84-92. [PubMed:12518026 ]
  6. Green RM, Hoda F, Ward KL: Molecular cloning and characterization of the murine bile salt export pump. Gene. 2000 Jan 4;241(1):117-23. [PubMed:10607905 ]
  7. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
  8. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ: The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998 Apr 17;273(16):10046-50. [PubMed:9545351 ]
  9. Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, Gasser R: Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 2001 Oct 5;167(1):83-98. [PubMed:11557132 ]
  10. Akita H, Suzuki H, Ito K, Kinoshita S, Sato N, Takikawa H, Sugiyama Y: Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys Acta. 2001 Mar 9;1511(1):7-16. [PubMed:11248200 ]
  11. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B: Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41. [PubMed:10692506 ]
  12. Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama Y: Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G159-67. Epub 2004 Aug 5. [PubMed:15297262 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
  2. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
  2. Wolters H, Elzinga BM, Baller JF, Boverhof R, Schwarz M, Stieger B, Verkade HJ, Kuipers F: Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J Hepatol. 2002 Nov;37(5):556-63. [PubMed:12399219 ]
  3. van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ: Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5. [PubMed:11408531 ]
  4. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, Meier PJ: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82. [PubMed:7557095 ]
  5. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557 ]
  6. Kullak-Ublick GA, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ: Functional characterization of the basolateral rat liver organic anion transporting polypeptide. Hepatology. 1994 Aug;20(2):411-6. [PubMed:8045503 ]
  7. Kanai N, Lu R, Bao Y, Wolkoff AW, Schuster VL: Transient expression of oatp organic anion transporter in mammalian cells: identification of candidate substrates. Am J Physiol. 1996 Feb;270(2 Pt 2):F319-25. [PubMed:8779893 ]
  8. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
  9. Kontaxi M, Echkardt U, Hagenbuch B, Stieger B, Meier PJ, Petzinger E: Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. J Pharmacol Exp Ther. 1996 Dec;279(3):1507-13. [PubMed:8968376 ]
  10. Li L, Lee TK, Meier PJ, Ballatori N: Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem. 1998 Jun 26;273(26):16184-91. [PubMed:9632674 ]
  11. Pang KS, Wang PJ, Chung AY, Wolkoff AW: The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6. [PubMed:9794920 ]
  12. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999 Jul;290(1):153-7. [PubMed:10381771 ]
  13. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
  14. Kullak-Ublick GA, Beuers U, Paumgartner G: Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology. 1996 May;23(5):1053-60. [PubMed:8621133 ]
  15. Hagenbuch B, Adler ID, Schmid TE: Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. [PubMed:10600646 ]
  16. Mendoza ME, Monte MJ, Serrano MA, Pastor-Anglada M, Stieger B, Meier PJ, Medarde M, Marin JJ: Physiological characteristics of allo-cholic acid. J Lipid Res. 2003 Jan;44(1):84-92. [PubMed:12518026 ]
  17. Lee TK, Koh AS, Cui Z, Pierce RH, Ballatori N: N-glycosylation controls functional activity of Oatp1, an organic anion transporter. Am J Physiol Gastrointest Liver Physiol. 2003 Aug;285(2):G371-81. Epub 2003 Apr 17. [PubMed:12702494 ]
  18. Hata S, Wang P, Eftychiou N, Ananthanarayanan M, Batta A, Salen G, Pang KS, Wolkoff AW: Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. Am J Physiol Gastrointest Liver Physiol. 2003 Nov;285(5):G829-39. Epub 2003 Jul 3. [PubMed:12842829 ]
  19. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol. 1996 Feb;270(2 Pt 2):F326-31. [PubMed:8779894 ]
  20. Satlin LM, Amin V, Wolkoff AW: Organic anion transporting polypeptide mediates organic anion/HCO3- exchange. J Biol Chem. 1997 Oct 17;272(42):26340-5. [PubMed:9334206 ]
  21. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y: Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. J Pharmacol Exp Ther. 1999 Feb;288(2):627-34. [PubMed:9918568 ]
  22. Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ, Hagenbuch B: Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol. 1999 Apr;276(4 Pt 1):G1037-42. [PubMed:10198348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Bile acid:sodium symporter activity
Specific Function:
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
Gene Name:
SLC10A2
Uniprot ID:
Q12908
Molecular Weight:
37713.405 Da
References
  1. Wolters H, Elzinga BM, Baller JF, Boverhof R, Schwarz M, Stieger B, Verkade HJ, Kuipers F: Effects of bile salt flux variations on the expression of hepatic bile salt transporters in vivo in mice. J Hepatol. 2002 Nov;37(5):556-63. [PubMed:12399219 ]
  2. Hallen S, Bjorquist A, Ostlund-Lindqvist AM, Sachs G: Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor. Biochemistry. 2002 Dec 17;41(50):14916-24. [PubMed:12475240 ]
  3. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227 ]
  4. Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. [PubMed:9458785 ]
  5. Saeki T, Matoba K, Furukawa H, Kirifuji K, Kanamoto R, Iwami K: Characterization, cDNA cloning, and functional expression of mouse ileal sodium-dependent bile acid transporter. J Biochem. 1999 Apr;125(4):846-51. [PubMed:10101301 ]
  6. Saeki T, Takahashi N, Kanamoto R, Iwami K: Characterization of cloned mouse Na+/taurocholate cotransporting polypeptide by transient expression in COS-7 cells. Biosci Biotechnol Biochem. 2002 May;66(5):1116-8. [PubMed:12092825 ]
  7. Lazaridis KN, Tietz P, Wu T, Kip S, Dawson PA, LaRusso NF: Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11092-7. [PubMed:10984521 ]
  8. Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA: Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol. 2000 Dec;279(6):G1188-200. [PubMed:11093941 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Hartmann G, Cheung AK, Piquette-Miller M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002 Oct;303(1):273-81. [PubMed:12235261 ]
  2. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759 ]
  3. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
  4. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001 ]
  5. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63. [PubMed:10358072 ]
  6. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
  2. Zelcer N, Saeki T, Bot I, Kuil A, Borst P: Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J. 2003 Jan 1;369(Pt 1):23-30. [PubMed:12220224 ]
  3. Zhang DW, Gu HM, Vasa M, Muredda M, Cole SP, Deeley RG: Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry. 2003 Aug 26;42(33):9989-10000. [PubMed:12924948 ]
  4. Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y: ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem. 2000 Jan 28;275(4):2905-10. [PubMed:10644759 ]
  5. Li T, Ito K, Horie T: Transport of fluorescein methotrexate by multidrug resistance-associated protein 3 in IEC-6 cells. Am J Physiol Gastrointest Liver Physiol. 2003 Sep;285(3):G602-10. [PubMed:12909565 ]
  6. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y: Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res. 2002 Jan;19(1):34-41. [PubMed:11837698 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
May be an organic anion pump relevant to cellular detoxification.
Gene Name:
ABCC4
Uniprot ID:
O15439
Molecular Weight:
149525.33 Da
References
  1. Zelcer N, Reid G, Wielinga P, Kuil A, van der Heijden I, Schuetz JD, Borst P: Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7. [PubMed:12523936 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mazzanti R, Fantappie O, Kamimoto Y, Gatmaitan Z, Gentilini P, Arias IM: Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles. Hepatology. 1994 Jul;20(1 Pt 1):170-6. [PubMed:7912687 ]
  2. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557 ]
  2. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem. 2002 Jul 26;277(30):26934-43. Epub 2002 May 13. [PubMed:12011098 ]
  3. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  3. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
  4. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557 ]
  5. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem. 2002 Jul 26;277(30):26934-43. Epub 2002 May 13. [PubMed:12011098 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate.
Gene Name:
SLCO4A1
Uniprot ID:
Q96BD0
Molecular Weight:
77192.505 Da
References
  1. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, Onogawa T, Suzuki T, Asano N, Tanemoto M, Seki M, Shiiba K, Suzuki M, Kondo Y, Nunoki K, Shimosegawa T, Iinuma K, Ito S, Matsuno S, Abe T: Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12. [PubMed:11316767 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Purine nucleotide transmembrane transporter activity
Specific Function:
Participates in physiological processes involving bile acids, conjugated steroids and cyclic nucleotides. Enhances the cellular extrusion of cAMP and cGMP. Stimulates the ATP-dependent uptake of a range of physiological and synthetic lipophilic anions, including the glutathione S-conjugates leukotriene C4 and dinitrophenyl S-glutathione, steroid sulfates such as dehydroepiandrosterone 3-sulfate...
Gene Name:
ABCC11
Uniprot ID:
Q96J66
Molecular Weight:
154299.625 Da
References
  1. Chen ZS, Guo Y, Belinsky MG, Kotova E, Kruh GD: Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol. 2005 Feb;67(2):545-57. Epub 2004 Nov 10. [PubMed:15537867 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Tohyama K, Kusuhara H, Sugiyama Y: Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91. Epub 2004 May 27. [PubMed:15166123 ]
  2. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).
Gene Name:
SLCO3A1
Uniprot ID:
Q9UIG8
Molecular Weight:
76552.135 Da
References
  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227 ]
  2. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y: Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 Apr;33(4):518-23. Epub 2005 Jan 7. [PubMed:15640378 ]
  3. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8. [PubMed:10973807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:
SLC16A1
Uniprot ID:
P53985
Molecular Weight:
53943.685 Da
References
  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PubMed:10579682 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Mendoza ME, Monte MJ, Serrano MA, Pastor-Anglada M, Stieger B, Meier PJ, Medarde M, Marin JJ: Physiological characteristics of allo-cholic acid. J Lipid Res. 2003 Jan;44(1):84-92. [PubMed:12518026 ]
  2. Hata S, Wang P, Eftychiou N, Ananthanarayanan M, Batta A, Salen G, Pang KS, Wolkoff AW: Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. Am J Physiol Gastrointest Liver Physiol. 2003 Nov;285(5):G829-39. Epub 2003 Jul 3. [PubMed:12842829 ]
  3. Mita S, Suzuki H, Akita H, Stieger B, Meier PJ, Hofmann AF, Sugiyama Y: Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump. Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G159-67. Epub 2004 Aug 5. [PubMed:15297262 ]
  4. Boyer JL, Ng OC, Ananthanarayanan M, Hofmann AF, Schteingart CD, Hagenbuch B, Stieger B, Meier PJ: Expression and characterization of a functional rat liver Na+ bile acid cotransport system in COS-7 cells. Am J Physiol. 1994 Mar;266(3 Pt 1):G382-7. [PubMed:8166278 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids.
Gene Name:
SLC51A
Uniprot ID:
Q86UW1
Molecular Weight:
37734.575 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids. Modulates SLC51A glycosylation, membrane trafficking and stability activities.
Gene Name:
SLC51B
Uniprot ID:
Q86UW2
Molecular Weight:
14346.195 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Cui Y, Konig J, Leier I, Buchholz U, Keppler D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem. 2001 Mar 30;276(13):9626-30. Epub 2000 Dec 27. [PubMed:11134001 ]
  2. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
  3. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. [PubMed:11375950 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Cystine:glutamate antiporter activity
Specific Function:
Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.
Gene Name:
SLC7A11
Uniprot ID:
Q9UPY5
Molecular Weight:
55422.44 Da
References
  1. Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31. [PubMed:8132774 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:24